Search Result

Results for "

colo205

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Cytotoxin (1) Adrenergic Receptor (1) Akt (2) Apoptosis (2) Autophagy (2) CDK (10) COX (1) Dopamine Receptor (1) ERK (2) Kinesin (1) P-glycoprotein (1) p38 MAPK (1) PROTACs (4) Smo (1)
By Research Areas:	Cancer (26) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143904

PROTAC TTK degrader-1	PROTACs	Cancer
PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-143905

PROTAC TTK degrader-2	PROTACs	Cancer
PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-153704

CDK4/6-IN-17	CDK	Cancer
CDK4/6-IN-17 (compound 12) is an orally active CDK4/6 inhibitor with IC₅₀ ranging of 10-100 nM in BE(2) cells. CDK4/6-IN-17 inhibits tumor growth in COLO205 xenograft model .

HY-143385

Cdc7-IN-12	CDK	Cancer
Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor with an IC₅₀ of <1 nM. Cdc7-IN-12 shows antiproliferative activities with IC₅₀ of 100-1000 nM in COLO205 cells. Cdc7-IN-12 has the potential for the research of cancer .

HY-143432

Cdc7-IN-18	CDK	Cancer
Cdc7-IN-18 (compound 1-2) is a potent CDC7 inhibitor with an IC₅₀ of 1.29 nM for Cdc7/DBF4 enzyme. Cdc7-IN-18 shows antiproliferative activities with IC₅₀ of 53.62 nM in COLO205 cells .

HY-149366

ABCB1-IN-1	P-glycoprotein	Cancer
ABCB1-IN-1 (compound 3) is a potent ABCB1 inhibitor. ABCB1-IN-1 induces cell apoptosis. ABCB1-IN-1 bearing 1-benzylimidazole has IC₅₀ values of 1.26 μM and 2.21 μM for Colo205 and Colo320 cells, respectively .

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .

HY-155764

COX-1/2-IN-4	COX	Cancer
COX-1/2-IN-4 (compound 2b) is anCOX inhibitorwith IC₅₀ values of 0.239 μM and 0.191 μM for COX-1 enzyme and COX-2 enzyme , respectively. COX-1/2-IN-4showsmoderateanticanceractivity against COLO205 and B16F1 cancer cell lines with IC₅₀ values of 30.79 and 74.15 μM, respectively .

HY-B1714A

NSC 601980	Others	Cancer
NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.

HY-B1714

NSC 601980 analog	Others	Cancer
NSC 601980 analog is the analog of the NSC601980, NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.

HY-112898

DC1SMe	ADC Cytotoxin	Cancer
DC1Sme, a DC1 derivative, exhibits IC₅₀ values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.

HY-N6002

3'-Hydroxypterostilbene 1 Publications Verification	Apoptosis Autophagy	Cancer
3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC₅₀s of 9.0, 40.2 and 70.9 µM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer .

HY-153350

ERK-IN-7

ERK Cancer

ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .
HY-112243

Cimpuciclib

CDK Inflammation/Immunology Cancer

Cimpuciclib is a selective CDK4 inhibitor (IC₅₀: 0.49 nM) that has anti-tumor activity .
HY-112243A

Cimpuciclib tosylate

CDK Inflammation/Immunology Cancer

Cimpuciclib tosylate is a selective CDK4 inhibitor (IC₅₀: 0.49 nM) that has anti-tumor activity .
HY-143387

Cdc7-IN-13

CDK Cancer

Cdc7-IN-13 (compound 84) is a potent CDC7 inhibitor with an IC₅₀ of <1 nM. Cdc7-IN-13 has the potential for the research of cancer .
HY-143389

Cdc7-IN-14

CDK Cancer

Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC₅₀ of <1 nM. Cdc7-IN-14 has the potential for the research of cancer .

ERK-IN-7	ERK	Cancer
ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .

Cimpuciclib	CDK	Inflammation/Immunology Cancer
Cimpuciclib is a selective CDK4 inhibitor (IC₅₀: 0.49 nM) that has anti-tumor activity .

Cimpuciclib tosylate	CDK	Inflammation/Immunology Cancer
Cimpuciclib tosylate is a selective CDK4 inhibitor (IC₅₀: 0.49 nM) that has anti-tumor activity .

Cdc7-IN-13	CDK	Cancer
Cdc7-IN-13 (compound 84) is a potent CDC7 inhibitor with an IC₅₀ of <1 nM. Cdc7-IN-13 has the potential for the research of cancer .

Cdc7-IN-14	CDK	Cancer
Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC₅₀ of <1 nM. Cdc7-IN-14 has the potential for the research of cancer .

HY-13224

AZD4877	Kinesin Apoptosis	Cancer
AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC₅₀ of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity .

HY-147744

AZD7254

Smo Cancer

AZD7254 is an orally active Smoothened (SMO) inhibitor with an EC₅₀ of 1.0 nM against sonic Hh protein (shh) .

AZD7254	Smo	Cancer
AZD7254 is an orally active Smoothened (SMO) inhibitor with an EC₅₀ of 1.0 nM against sonic Hh protein (shh) .

HY-151613

MS15	PROTACs Akt	Cancer
MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively .

HY-151613A

MS15 TFA	PROTACs Akt	Cancer
MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively .

HY-113825

CLK1/2-IN-1

CDK Cancer

CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}
HY-113670

CLK1/2-IN-2

CDK Cancer

CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

CLK1/2-IN-1	CDK	Cancer
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

CLK1/2-IN-2	CDK	Cancer
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-122872

MKK7-COV-9	p38 MAPK	Cancer
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

HY-14543

Sertindole 2 Publications Verification Lu 23-174	5-HT Receptor Dopamine Receptor Adrenergic Receptor Autophagy	Neurological Disease Cancer
Sertindole (Lu 23-174) is an orally active 5-HT_2A, 5-HT_2C, dopamine D₂, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells .

3'-Hydroxypterostilbene 1 Publications Verification	Structural Classification Stilbenes Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer Sphaerophysa salsula	Apoptosis Autophagy
3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC₅₀s of 9.0, 40.2 and 70.9 µM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

colo205

Inhibitors & Agonists

NaturalProducts

Natural
Products